Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556490 · ClinicalTrials.gov registry record · NA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 526
- Enrollment target
NCT01556490: Completed NA study, sponsored by Boston Scientific Corporation.
NCT01556490 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 526 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556490, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 526 participants
- Enrollment target
Study Summary
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Primary Outcome
Time from randomization until date of death due to any cause as reported by study site.
Interventions
- DEVICE TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2012-03 |
| Est. Completion | 2022-04-30 |
| Phase | NA |
What the finished NCT01556490 record still lists
NCT01556490 is an interventional study that assigns participants to a tested intervention. The registered 526 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01556490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01556490 about?
NCT01556490 is a clinical study titled "Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer". The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
What is the current status of trial NCT01556490?
This trial is currently completed. It is a NA study. The enrollment target is 526 participants. The study started on 2012-03. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT01556490?
The interventions under investigation include: TheraSphere (DEVICE).
Who is sponsoring clinical trial NCT01556490?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01556490's enrollment target sits among peer trials
526 189th of 2000 higher than 1,812 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04738825 · 526 participants · NA
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia